Abstract
Recent investigations analyzed in depth the biochemical and biophysical properties of the endothelial glycocalyx. In comparison, this complex cell-covering structure is largely understudied in alveolar epithelial cells. To better characterize the alveolar glycocalyx ultrastructure, unaffected versus injured human lung tissue explants and mouse lungs were analyzed by transmission electron microscopy. Lung tissue was treated with either heparinase (HEP), known to shed glycocalyx components, or pneumolysin (PLY), the exotoxin of Streptococcus pneumoniae not investigated for structural glycocalyx effects so far. Cationic colloidal thorium dioxide (cThO2) particles were used for glycocalyx glycosaminoglycan visualization. The level of cThO2 particles orthogonal to apical cell membranes (≙ stained glycosaminoglycan height) of alveolar epithelial type I (AEI) and type II (AEII) cells was stereologically measured. In addition, cThO2 particle density was studied by dual-axis electron tomography (≙ stained glycosaminoglycan density in three dimensions). For untreated samples, the average cThO2 particle level was ≈ 18 nm for human AEI, ≈ 17 nm for mouse AEI, ≈ 44 nm for human AEII and ≈ 35 nm for mouse AEII. Both treatments, HEP and PLY, resulted in a significant reduction of cThO2 particle levels on human and mouse AEI and AEII. Moreover, a HEP- and PLY-associated reduction in cThO2 particle density was observed. The present study provides quantitative data on the differential glycocalyx distribution on AEI and AEII based on cThO2 and demonstrates alveolar glycocalyx shedding in response to HEP or PLY resulting in a structural reduction in both glycosaminoglycan height and density. Future studies should elucidate the underlying alveolar epithelial cell type-specific distribution of glycocalyx subcomponents for better functional understanding.
Keywords: Alveolar epithelial glycocalyx, Thorium dioxide, Heparinase, Pneumolysin, Electron tomography, Lung stereology
Introduction
First mentions of an "externous coat" around cells go back almost a century, followed by decades of histochemical methods to reveal its morphology (Martins and Bairos 2002). In the early 1960s, Bennett proposed the term “glycocalyx “ (derived from Greek: glykys = sweet, kalyx = husk) (Bennett 1963), which perfectly describes a main structural feature: a carbohydrate-enriched layer coating nearly all free parts of cell membranes. More recent research classifies glycocalyx glycans depending on their linkage to proteins or lipids into proteoglycans, glycoproteins, glycolipids, and free glycans (Mockl 2020). For many cell types, including both alveolar epithelial type I (AEI) and type II (AEII) cells, mass ratios of the different glycocalyx subcomponents are not available so far. However, there has been growing recognition that glycosaminoglycans (GAGs) constitute a major component being responsible for many common glycocalyx stainings due to their negative charge properties. Glycocalyx GAGs are long, linear glycans that can be found covalently bound to core proteins, constituting the class of proteoglycans, whereas heparan and chondroitin sulfate represent classical bound GAGs on the alveolar epithelium (Haeger et al. 2018; Bray 2001). The more simple non-protein non-sulfated glycan hyaluronan makes up a further major alveolar glycocalyx GAG (Bray 2001).
In general, GAGs present on cell surfaces and in the extracellular matrix are known to regulate a variety of biophysical and biochemical tissue properties, whereby alterations in their distribution or composition are often associated with major pathophysiological changes in cells and organs (Morla 2019; Gesslbauer et al. 2013; Wang and Chi 2022). The specific functions of lung epithelial glycocalyx GAGs, especially those on AEI and AEII, are relatively unexplored despite their important localization at the immediate interface between organism and environment. Growing evidence implicates alveolar GAGs in air–blood barrier permeability, surfactant and aqueous hypophase homeostasis, pathogen binding as well as alveolar development and injury (Ochs et al. 2020; Rizzo et al. 2022; Martins and Bairos 2002; Weidenfeld and Kuebler 2018; Haeger et al. 2016, 2018; LaRiviere et al. 2020; Wigen et al. 2019; Rizzo and Schmidt 2023). To date, however, there are still no sufficient quantitative and qualitative microscopic data on the alveolar epithelial glycocalyx GAG distribution in physiological and pathophysiological settings. Thus, there is a lack of reference values for future studies which should better reveal in depth the morphological and functional properties of the alveolar epithelial glycocalyx. Hence, the present study aimed to characterize the ultrastructurally unremarkable and affected alveolar glycocalyx by transmission electron microscopy (TEM). To this end, we treated human lung explants and mouse lungs with either heparinase (HEP) as an established glycocalyx-shedding enzyme or with pneumolysin (PLY), a bacterial exotoxin known for its ability to induce lung injury but unrelated to structural alveolar epithelial glycocalyx changes so far.
Heparinase-specific shedding of alveolar epithelial glycocalyx
Given the close association of acute lung injury with alveolar glycocalyx degradation (Rizzo et al. 2022; Haeger et al. 2016, 2018; LaRiviere et al. 2020), selective GAG shedding provides a useful reference model for collecting ultrastructural data for comparison with PLY. Bacterial HEP enzymes specifically degrade heparan sulfate and heparin chains (Boyce and Walsh 2022). The GAG heparan sulfate is not only a common proteoglycan component on the alveolar epithelium, but is also present on almost all cell types as well as in basement membranes and extracellular matrices in various tissues due to its general involvement in physiological activities (Hayashida et al. 2022; Collins and Troeberg 2019). The synthesis and degradation of heparan sulfate represents a critical and sensitive, tightly controlled process. Of note, heparan sulfate can be depolymerized by the mammalian enzyme heparanase, which not only ensures continual provision of effective synthesis products under physiological conditions, but is also a major regulator in pathophysiological processes such as inflammation, sepsis, and cancer (Boyce and Walsh 2022; Collins and Troeberg 2019; Wu and Davies 2020; Sanderson et al. 2017).
Pneumolysin—unknown effects on alveolar epithelial glycocalyx
Streptococcus pneumoniae invasion is a major cause of pneumonia, sepsis, and meningitis worldwide, being a leading cause of death especially among infants, young children, and patients with multi-morbidity (Briles et al. 2019). This bacterium produces the pore-forming virulence factor PLY, which favors its penetration into the interstitium and dissemination into the bloodstream (Witzenrath et al. 2006b; Rubins et al. 1995; Woodhead 2002; Cockeran et al. 2002). In addition, PLY might separate tight junctions (Rayner et al. 1995). More recent research has shown interactions with several other host molecules in a pro- and anti-inflammatory manner (Pereira et al. 2022). Alveolar epithelial glycocalyx alteration by PLY would be a conceivable further effect related to lung injury, but has not been investigated so far.
Cationic hydrous thorium dioxide colloids—glycocalyx visualization
To date, research has shown that the alveolar lining layer mainly consists of water, surfactant, and glycocalyx components. In contrast to surfactant, visualizing the delicate, dynamically organized glycocalyx is a challenging task, whereby its detailed architecture can only be resolved at the TEM level (Ochs et al. 2020). Cryoprocessing might be most capable of preserving the alveolar epithelial glycocalyx in its native state. However, current protocols for fixing native lung tissue by high pressure freezing do not provide a suitable approach for quantitative stereological TEM analyses since most alveoli collapse. Therefore, the current study evaluated chemically fixed, conventionally embedded lung samples. Many staining reagents have been used over the decades of glycocalyx studies. Best known are certainly ruthenium red and alcian blue. In addition, colloidal iron, phosphotungstic acid, lanthanum nitrate, or lectins (concanavalin A, wheat germ agglutinin, and peanut agglutinin) were used as well (Ochs et al. 2020). Staining with cationic hydrous thorium dioxide colloids (cThO2) dates back to the late 1920s, where it was used as the X-ray contrast medium “Thorotrast” (Dickson 1932) until carcinogenic effects became known (Stover 1983). Half a century later, cThO2 was rediscovered and made available as a useful contrast agent for TEM due to its capacity to bind acid GAGs (Groot 1981). In comparison to other staining reagents like alcian blue, ruthenium red, and positive colloidal iron, cThO2 particles with a size of around 1 to 1.7 nm show better penetration into the tissue and higher electron density easily detected by TEM (Groot 1981; Hegermann et al. 2016; Lünsdorf et al. 2006). But despite these advantages, cThO2 remains less suitable for routine examinations, which is attributed to its radioactivity that requires strict approval as well as careful handling. CThO2 treatment of fixed samples prior to embedding also allows for three-dimensional (3D) analysis using electron tomography (ET).
Material and methods
Human lung tissue, treatment, and fixation
Fresh human lung tissue explants were obtained from two female patients (52 and 78 years old) suffering from lung carcinoma, who underwent lung resection at local thoracic surgeries. Both patients had a history of chronic obstructive pulmonary disease (patient 1 in early and patient 2 in advanced stage). The study was approved by the ethics committee (Charité-Universitätsmedizin Berlin, Germany, EA2/079/13). Written informed consent was obtained from both patients.
Macroscopically unremarkable (tumor-free) peripheral human lung tissue was dissected into small pieces (1 mm × 1 mm × 3 mm) and incubated for 1 h at 37 °C in Roswell Park Memorial Institute (RPMI) 1640 medium (Gibco by Life Technologies, Carlsbad, CA, USA) either with HEP (2 U/400 µl) (heparinase I and III blend from Flavobacterium heparinum, H3917, Sigma-Aldrich, St. Louis, MO, USA) (n = 2 from patient 1, n = 1 from patient 2) or with PLY (0.08 µg/400 µl) (provided by Timothy Mitchell; Mitchell et al. 1989) (n = 2 from patient 1, n = 1 from patient 2). For comparison with untreated human lung, tissue pieces (n = 2 from patient 1, n = 1 from patient 2) were incubated for 1 h in pure RPMI medium (400 µl). Subsequently, all tissues were fixed and stored in 0.15 M HEPES (Roth, Karlsruhe, Germany) (pH 7.35) containing 1.5% paraformaldehyde and 1.5% glutaraldehyde (both from Serva, Heidelberg, Germany).
Mouse lung tissue, treatment, and fixation
Nine female C57Bl/6 mice were housed under specific-pathogen-free conditions with free dietary access for 16 to 19 weeks before treatment. Animal procedures were approved by institutional authorities (“Tierschutzbeauftragte” and “Tierschutzausschuss” of the Charité—Universitätsmedizin Berlin, Germany) and local governmental authorities (State Office for Health and Social Affairs Berlin, Germany).
Mice were anesthetized and heparinized with Ketamin (165–250 mg/kg body weight) and Xylazin (15–25 mg/kg body weight) diluted in 0.9% sodium chloride (NaCl) solution with 50% heparin (5000 IU/ml). After laparotomy and exsanguination by cutting the vena cava caudalis, animals were tracheotomized and ventilated. Following sternotomy and cannulation of the left atrium and pulmonary artery, the lungs were perfused with 37 °C sterile Krebs–Henseleit hydroxyethylamylopectin buffer (1 ml/min) (Serag-Wiesner AG, Naila, Germany) and ventilated by negative pressure (Pexp −4.5, Pins −9.0 cmH2O) in a humidified chamber (Witzenrath et al. 2006a). To ensure stable experimental conditions, a 20-min baseline was performed before stimulation (e.g., to control chamber pressure, tidal volume, and pulmonary artery pressure). Then, an intratracheal bolus of either HEP in 0.9% NaCl solution (0.625 U/25 µl) (n = 3) or PLY in 0.9% NaCl solution (1 µg/25 µl) (n = 3) or distilled water in 0.9% NaCl solution (0.15 µl/25 µl) (n = 3) was aerosolized with a microsprayer (Penn-Century, Wyndmoor, PA, USA). Mice were ventilated for further 30 min. This time period was chosen because PLY stimulation is known to produce marked hyperpermeability of the pulmonary barrier after 30 min of intratracheal aerosolization (Witzenrath et al. 2006b). Then, mouse lungs were removed and immediately fixed by intratracheal instillation with 0.15 M HEPES (pH 7.35) containing 1.5% paraformaldehyde and 1.5% glutaraldehyde under pressure of a 20 cmH2O. Lungs were removed, stored in the fixative at 4 °C for 1 week, and cut into small pieces (1 mm × 1 mm × 1 mm). Three pieces each were randomly selected from all mouse lung samples.
Staining with ThO2 particles, embedding, and sectioning
To increase the specificity of negatively charged glycocalyx components, lung tissue pieces were immersed in a low-pH solution (pH 3) of 100 mM sodium acetate buffer for 5 min, followed by incubation in 0.5% cThO2 in sodium acetate for 5 min and again in sodium acetate for 5 min. During every step, samples were gently massaged with a wooden skewer to allow the solutions to be distributed in the alveoli. After the cThO2 treatment, samples were stored in 0.15 M HEPES (pH 7.35) containing 1.5% paraformaldehyde and 1.5% glutaraldehyde until further processing. Samples were osmicated with 1% OsO4 (Electron Microscopy Sciences, Hatfield, PA, USA) in 0.1 M cacodylate buffer for 2 h at room temperature followed by incubation in half-saturated (4%) aqueous uranyl acetate (Merck, Burlington, MA, USA) over night at 4 °C. Between the solution-changing steps, samples were washed with 0.15 M HEPES and 0.1 M cacodylate buffer. After dehydration in a graded acetone series, the samples were transferred to Epon resin (Serva, Heidelberg, Germany).
For quantitative stereological two-dimensional TEM analysis, ultra-thin sections (70 nm) of all samples were prepared with an Ultra 45° diamond knife (DiATOME, Nidau, Switzerland) at an ultramicrotome (Leica UltraCut S, Wetzlar, Germany) and contrasted with Reynolds' lead citrate (Reynolds 1963) (Merck, Burlington, MA, USA). For qualitative ET analysis, semi-thin sections (250 nm) of control and treated human tissue explants were prepared and cut with an Ultra Semi diamond knife (DiATOME, Nidau, Switzerland) as previously described in Lettau et al. ( 2022). Sections were contrasted with Reynolds’ lead citrate, and for tilt series alignment, incubated with fiducial 10 nm standard gold nanoparticles (Cytodiagnostics, Burlington, ON, Canada) from both sides for 3 min each and finally dried with filter paper.
Stereological measurements and statistical analysis
The investigator was blinded for work at the microscope and measurements. Examination of the grids were carried out with a Zeiss Leo 906 electron microscope at 80 kV acceleration voltage (Zeiss, Oberkochen, Germany) equipped with a slow-scan 2 K charge-coupled device (CCD) camera (TRS-Tröndle, Moorenweis, Germany) with associated software Image SP (version 1.2.890). The regions of interest were the apical membranes of human and mouse AEI and AEII. The field of view was defined to the rules of systematic uniform random area sampling (Tschanz et al. 2014). All images for measurements were prepared in the same ×35.970 on-microscope magnification. The measurements of cThO2 particle levels (≙ stained glycosaminoglycan height) were planned as orthogonal intercept lengths (Jensen et al. 1979). That means a grid of lines (100 nm line distance) was placed over the images via the grid plugin tool from open-source software ImageJ (version 1.52). The orthogonal distance from the clearly visible cell membrane cut by a line to the end of the cThO2 stained glycocalyx was measured using the lining tool from ImageJ (Fig. 1e and f). Cut membranes that were not clearly identifiable due to orientation or overlap within the section were not included in the analysis. If there was more than one possible direction due to undulating shape, the shortest path was followed. In total, we measured a minimum of 100 counting events in each human and mouse sample for all treatment groups (control, HEP, PLY).
Data analyses were performed using GraphPad Prism version 9 (GraphPad Software, USA). Distribution of data was assessed with the Shapiro–Wilk test. Normally distributed data were compared with two-way analysis of variance (ANOVA) followed by the Sidak–Holm post hoc test. Data not normally distributed were analyzed by the Kruskal–Wallis test followed by Dunn’s post hoc test. A P value < 0.05 was considered statistically significant.
The software programs GraphPad Prism version 9 and Adobe Photoshop version 2021 (Adobe Systems Software Ireland Limited, Republic of Ireland) were used to create figures and graphics (Figs. 1, 2, and 3).
ET and 3D analysis
After 20 min pre-irradiation of the regions of interest (apical human AEII membranes), tilt series of these regions were acquired with a Tecnai G2 TEM (FEI, Eindhoven, Netherlands) with integrated software Tecnai User Interface (version 4.6) with Xplore3DTM software and TEM Imaging and Analysis (version 4.7 SP1) at 200 kV and ×55.000 on-microscope magnification and automatically recorded with a 2 K CCD camera (Olympus SIS, Münster, Germany) (binning 1) in a range from 60° to −60° in steps of 1°. To reduce the common "missing wedge" artifacts (Paavolainen et al. 2014; Koster et al. 1997; Donohoe et al. 2006), we recorded all tilt series from two perpendicular tilt axes (dual-axis ET).
The open-source software package IMOD (version 4.11) was used for further processing of raw ET data. IMOD's etomo was used for 3D reconstruction of the dual-axis tilt series. The calculation was done with an R-weighted back-projection algorithm of the aligned stack. The original tomogram pixel size of 1.84 nm in the x-, y-, and z-direction was maintained for the subsequent analyses. Analyses of cThO2 particle density (≙ stained glycosaminoglycan density in three dimensions) were performed using IMOD's 3dmod modeling and display program. Technical details of tomogram generation and tools used for analysis, especially the automatic isosurface, are described in detail on the IMOD homepage: https://bio3d.colorado.edu/imod/ (last accessed March 10, 2023).
Microsoft PowerPoint version 2016 (Microsoft Corporation, USA) was used to create figures (Fig. 4 and Fig. 5).
Results
The following results refer to all electron-dense particles on the alveolar epithelium, which can be assumed to be glycocalyx GAG-bound cThO2 particles. CThO2 particles were recognizable in all analyzed samples.
Stereological analysis of alveolar epithelial cThO2 particle levels
All apical alveolar epithelial cell membranes in human and mouse control samples showed a thin cThO2 particle layer (Fig. 1a, b). On closer inspection, a distinction in the level and density of cThO2 particles was already evident in the qualitative examination, as AEI exhibited fewer cThO2 particles in the xy-dimension compared to AEII (Fig. 1b–d). Measurements of cThO2 particle levels as orthogonal intercepts for quantitative analysis (see methods section) is exemplified in Fig. 1e, f. All measured mean values (with standard deviation) listed below are summarized in Table 1. The average level of cThO2 particles was for control human AEI 18.10 nm (2.33 nm) and mouse AEI 16.92 nm (1.69 nm), for human AEII 43.85 nm (0.50 nm) and for mouse AEII 35.33 nm (2.88 nm) (Fig. 2a, d, f, and i). While the cThO2 particle level on human and mouse AEI was relatively continuous, there were locally larger extensions on AEII cells, especially microvilli-associated with measurements of up to a 149 nm cThO2 particle level in human and 138 nm in mouse control samples (Fig. 2e and j).
Table 1.
Control AEI | HEP AEI | PLY AEI | Control AEII | HEP AEII | PLY AEII | |
---|---|---|---|---|---|---|
Human | ||||||
Mean cThO2 level sample 1 (SD) [nm] | 19.60 (8.48) | 12.85 (6.15) | 15.23 (8.76) | 43.30 (22.03) | 23.12 (13.50) | 25.95 (10.33) |
Mean cThO2 level sample 2 (SD) [nm] | 19.29 (7.16) | 13.27 (4.99) | 13.33 (6.13) | 43.99 (21.10) | 21.28 (7.99) | 24.14 (12.37) |
Mean cThO2 level sample 3 (SD) [nm] | 15.42 (6.99) | 13.42 (6.18) | 13.45 (5.32) | 44.26 (20.47) | 25.11 (13.34) | 23.75 (12.87) |
Average of means (SD) [nm] | 18.10 (2.33) | 13.18 (0.29) | 14.00 (1.06) | 43.85 (0.50) | 23.17 (1.92) | 24.62 (1.18) |
Mouse | ||||||
Mean cThO2 level mouse 1 (SD) [nm] | 16.14 (6.82) | 12.82 (4.47) | 10.39 (4.42) | 32.02 (20.47) | 19.67 (7.97) | 19.46 (7.18) |
Mean cThO2 level mouse 2 (SD) [nm] | 15.76 (6.83) | 11.95 (5.03) | 11.05 (4.20) | 37.31 (10.14) | 19.30 (6.69) | 20.64 (6.98) |
Mean cThO2 level mouse 3 (SD) [nm] | 18.85 (8.16) | 12.92 (4.69) | 11.59 (5.85) | 36.64 (22.87) | 19.76 (7.17) | 20.16 (8.06) |
Average of means (SD) [nm] | 16.92 (1.69) | 12.56 (0.54) | 11.01 (0.60) | 35.33 (2.88) | 19.58 (0.24) | 20.09 (0.59) |
Both treatments resulted in significant reduction of cThO2 particle levels (Fig. 2b–e and g–j). There was a reduction of about 47% (HEP) and 44% (PLY) on human AEII and about 45% (HEP) and 43% (PLY) on mouse AEII. The effect was somewhat less pronounced on AEI with a reduction of about 27% (HEP) and 23% (PLY) on human AEI and about 26% (HEP) and 35% (PLY) on mouse AEI. Values after treatment: human AEI 13.18 nm (0.29 nm) (HEP) and 14.00 nm (1.06 nm) (PLY); mouse AEI 12.56 nm (0.54 nm) (HEP) and 11.01 nm (0.60 nm) (PLY); human AEII 23.17 nm (1.92 nm) (HEP) and 24.62 nm (1.18 nm) (PLY); mouse AEII 19.58 (0.24 nm) (HEP) and 20.09 nm (0.59 nm) (PLY). In addition, as qualitative observation, the HEP and PLY groups showed a decrease in the density of cThO2 particles on both AEI and AEII. At lower magnifications on the microscope, the cThO2 layer appeared rather punctate or patchy, with individual cThO2 particles visible only at higher magnifications for the measurements. This effect was particularly pronounced in the human samples.
We also detected cThO2 particles on intra-alveolar surfactant subtypes, including tubular myelin, in both human and mouse samples (Fig. 3a). In addition, the HEP- and PLY-treated samples showed partially fragmented and disorganized surfactant components (Fig. 3b and c).
3D analysis of cThO2 particle distribution via dual-axis ET
To better understand the quantitative xy-dimension measurements in the z-dimension and the qualitative finding of different cThO2 particle densities under different alveolar conditions, we exemplarily analyzed the 3D distribution of cThO2 particles on apical AEII membranes in human control, HEP and PLY semi-thin sections. Dual-axis data generation and analysis turned out to be distinctly better than single-axis analysis. In the latter, cThO2 particle aggregates appeared comparatively blurred and skewed. In contrast to the conventionally analyzed ≈ 70 nm thick sections, the ≈ 2 nm thick virtual tomogram slices exhibited “shadow-like” effects at many locations in close proximity to the glycocalyx (Fig. 4a). This phenomenon was caused by the strong signal of cThO2 particles radiating into the preceding and following virtual slices. Due to the different electron density from the very electron-dense cThO2 particles that was no obstacle for 3D model generation.
IMOD’s isosurface function was used to create computer-based cThO2 particle signal analysis (Fig. 4b, c). The models of human control AEII showed an extensive cThO2 particle distribution with many interconnections which can be observed between microvilli (Fig. 4d) and only few very small gaps to the cell membrane. In contrast, virtual tomogram slices and 3D models after HEP (Fig. 5a) and PLY (Fig. 5b) treatment looked somewhat frayed as in the ultra-thin sections. A reduced cThO2 particle density after the treatment, which was qualitatively observed in the conventional evaluation in the xy-dimension, was confirmed in the z-dimension (Fig. 5c). A reduced cThO2 particle density became more apparent. Compared to the control model, HEP and PLY models showed changes in the form of many cThO2 gaps of different sizes towards the cell membrane. Considering the altered cThO2 model under PLY, we examined areas with well-preserved membranes in virtual sections more closely for possible pores and other membrane defects that would explain GAG loss. However, membranes with absent cThO2 particles appeared intact as well (Fig. 5b).
Discussion
Our study provides quantitative and qualitative electron microscopic data on the cell-specific alveolar epithelial glycocalyx GAG distribution and shows that specific HEP-induced GAG shedding is associated with a decrease in cThO2 particle level and density. We found a comparable GAG shedding under the influence of PLY, for which the exact mechanism remains to be elucidated.
The present investigation is a comparative evaluation based on cThO2 particle staining patterns. Like cThO2, many conventional glycocalyx stainings rely on electrostatic interactions that mark GAG components only, the glycocalyx, however, is neither complete nor specific like immunocytochemistry. The native glycocalyx expansion may differ as well as staining patterns of other methods, which should be further studied. In addition, superposition artifacts must be considered for measurements in both native and fixed stained sections when using conventional TEM analyses. Due to the section thickness and orientation, several glycocalyx layers are measured in the z-direction. Moreover, not all these glycocalyx layers are oriented perpendicular to the visualized membrane surface given the isotropic alignment of lung tissue. These non-perpendicular perspectives cause the cThO2 particle level to appear longer than it actually is. Correction factors for determining the actual length from orthogonal intercepts of microscopic sections have already been determined for measuring membrane thickness (Jensen et al. 1979). This does not change statistics, but such factors become important and have to be developed for studies on exact expansion of native glycocalyx. However, it must be considered that to date, no microscopical method can provide results that are not distorted in some way by the preparation (i.e., embedding, cutting, beam).
ET partly avoids the above described superposition artifacts by achieving a resolution of ≈ 2 nm in all three dimensions. Using this technique, it is important to consider that the long electron beam illumination of the tilt series causes tissue shrinkage in the z-direction, leading to a compressed appearance of the particles in the xz- and yz-direction (Luther 2006) but not in the xy-direction, if the section is well attached to the film (Luther 2006; Laue et al. 2021). However, since the number of bound cThO2 particles does not change, qualitative analysis of densities is perfectly feasible. The size and electron density of cThO2 proved to be excellent properties for computer-based generation of 3D distribution models. Analyzing these models, we determined that glycocalyx shedding is structurally reflected not only in the quantified reduction of cThO2 particle levels but also in a reduction of cThO2 particle density. Including density values, measured HEP and PLY treatment damage may reach higher percentage values and should be considered in future studies. In addition, the methodological impact on shedding rates should be further investigated. Thus, mice treatment with HEP resulted in significant GAG detachments even at much lower concentrations than used in other studies (Rizzo et al. 2022; Haeger et al. 2018). In the literature, data on the range of activity and corresponding structural and functional alveolar glycocalyx effects are missing so far.
CThO2-stained GAG levels in human and mouse lungs measured in this study are significantly lower in AEI compared with AEII. Earlier investigations, including a study by our group, already indicated a different staining pattern between these two cell types in qualitative analyses (Kuhn 1968; Adamson and Bowden 1970; Roth 1973; Ochs et al. 2020). The functional reason for lower level of glycocalyx GAGs on AEI has not been investigated yet, but a major factor might be gas exchange, which must be provided by flat AEI covering ≈ 95% of the alveolar surface. The opposite endothelial glycocalyx in pulmonary capillaries is also very thin relative to other capillaries, supporting the theory of diffusion function (Suzuki et al. 2022). In contrast, cuboidal AEII located in the alveolar corners have secretion and renewal functions (Ochs et al. 2020). Studies on the individual distribution of glycocalyx subcomponents on AEI and AEII in health and disease, including fetal and senescent time points, could therefore be of potential value to elicit possible cell type-specific functions. It is further to mention that the pathophysiological condition of chronic obstructive pulmonary disease was reported to be accompanied by elevated endogenous heparanase expression (Morris et al. 2015). Considering the affected human lungs used in our study, AEI and AEII GAG expansion could differ from completely healthy lungs. The slightly higher control AEI and AEII measurements of human compared to mouse lung tissue might be related, in part, to the fact that human lung alveoli are also larger than those of mice (Irvin and Bates 2003; Vignero et al. 2018). The gender could impact measurements as well. The present data are exclusively based on female human and mouse lungs. Rizzo et al. (2022) recently found increased GAG shedding in patients with acute respiratory distress syndrome in the airspace to be associated with male gender.
In contrast to the epithelial glycocalyx, the endothelial glycocalyx has been previously recognized and studied as an essential structure for endothelial function, with alterations described in various acute and chronic diseases (Foote et al. 2022; Patterson et al. 2022; Uchimido et al. 2019; Masola et al. 2021; Puchwein-Schwepcke et al. 2021). However, there is growing evidence that the alveolar epithelial glycocalyx plays an important role in regulating inflammation, infection, and allergic processes (Chignalia et al. 2016) and that acute lung injury is associated with alveolar glycocalyx degradation (Rizzo et al. 2022; Haeger et al. 2016, 2018; LaRiviere et al. 2020). We found alveolar epithelial glycocalyx GAG shedding under subcytolytic PLY dosages with similar patterns to HEP-induced shedding. Whether PLY predominantly impacts on heparan sulfate detachment as well, or other GAGs and anchoring proteins such as sydecan-1 might be addressed, needs to be explored by specific stainings. Likewise, effects of different PLY concentrations upon the underlying processes are to be examined. Alveolar glycocalyx degradation during intratracheal lipopolysaccharide-induced lung injury has been previously described, whereby the release of heparan sulfate from the epithelium was discussed to inhibit the spread of infection (Haeger et al. 2018). A mechanism of lipopolysaccharides was shown to be the induction of matrix metalloproteinase expression, capable of cleaving proteoglycans (Zhang et al. 2021; Rizzo and Schmidt 2023). Streptococcus pneumoniae, like other bacteria, uses heparan sulfate as a receptor to adhere to host cells and infect them (Rajas et al. 2017; Bernfield et al. 1999; Aquino et al. 2022). GAG antagonists have been shown to inhibit such microbial attachment and invasion of host cells in vitro and decrease virulence in vivo (Bartlett and Park 2010). In addition, soluble heparan sulfate may function as a decoy receptor (Haeger et al. 2018; Chandra et al. 2019). In this context, recent research investigates the utility of heparin to remove pathogens from the blood, as many bacteria bind to heparin similarly to heparan sulfate (Seffer et al. 2021). Furthermore, endothelial glycocalyx degradation via heparanase activation has already been demonstrated in the pathophysiological process of acute lung injury (Schmidt et al. 2012; Li et al. 2020), in which an aberrant epithelial heparanase expression might be assumable as well. Moreover, it has recently been shown in vitro that PLY can induce the release of the GAG hyaluronan from human lung endothelial cells in response to the production of reactive oxygen species (Sauer et al. 2022). Finally, interactions of PLY with the phospholipid bilayer (Nollmann et al. 2004) could disrupt the integrity of GAGs within the membrane, leading to shedding.
As previously described (Ochs et al. 2020), we observed cThO2 particles on surfactant subtypes in the alveolar hypophase. Specific staining of glycocalyx subcomponents should follow to reliably identify potential glycocalyx–surfactant interactions. A feasible GAG candidate would be hyaluronan whose polar heads are thought to attract surfactant phospholipids and interact with the hydrophobic surfactant proteins B and C (Bray 2001). Studies indicate improved biophysical activity of surfactant by this GAG (Souza-Fernandes et al. 2006; Lu et al. 2005a, 2005b; Lopez-Rodriguez et al. 2013). Heparan sulfate is conceivable as well, since heparin as a highly sulfated form of heparan sulfate can bind to surfactant proteins A, B, and D, and selective GAG shedding by HEP has been described sufficient to induce surfactant dysfunction in mice (Rizzo et al. 2022). Further candidates of interest are the hydrophilic surfactant proteins A and D which may interact with the glycocalyx via a specific carbohydrate recognition domain possibly influencing their primarily immunomodulatory functional capacities (Ochs et al. 2020).
In conclusion, our study demonstrates a glycocalyx GAG layer on the alveolar epithelium that is morphologically distinguishable between AEI and AEII. In humans and mice, the glycocalyx GAGs of both cell types respond to lung injury induced by HEP and PLY in a similar pattern with a loss of GAG height and density. There is thus a need to better understand the underlying cell type-specific distribution of glycocalyx subcomponents to achieve a comprehensive understanding of physiological and pathophysiological conditions.
Acknowledgements
The authors thank Petra Schrade (Core Facility Electron Microscopy, Charité—Universitätsmedizin Berlin, Germany), John Horn and Vladimir Gluhovic (both Institute of Functional Anatomy, Charité—Universitätsmedizin Berlin, Germany) for excellent technical assistance and Christina Brandenberger (Institute of Functional Anatomy, Charité—Universitätsmedizin Berlin, Germany) and Dominik Hans Willi Leitz (Department of Pediatrics, Division of Pneumonology and Immunology, Charité—Universitätsmedizin Berlin, Germany) for fruitful discussions.
Author contributions
ST: manuscript—original draft, visualization (TEM, ET), data curation, formal analysis, performed experiments (cThO2 staining, sectioning). ML: manuscript—original draft, visualization (IMOD), data curation, formal analysis. JH: manuscript—editing, performed experiments (cThO2 staining). MLR: manuscript—review & editing. SW: manuscript—editing, performed experiments (human lung tissue treatment). BG: manuscript—editing, performed experiments (mouse lung preparation and treatment). DF: manuscript—editing, performed experiments (human lung tissue preparation). GN: manuscript—editing, conceptualization. ELR: manuscript—editing. AH: manuscript—editing, conceptualization. SH: manuscript—editing, conceptualization. MW: manuscript—editing, conceptualization. WMK: manuscript—editing, conceptualization. MO: manuscript—editing, conceptualization.
Funding
Open Access funding enabled and organized by Projekt DEAL. Funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)-SFB 1449-431232613.
Data availability
The datasets generated and analyzed during the current study are available from the corresponding authors on reasonable request.
Declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Footnotes
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Sara Timm and Marie Lettau have contributed equally to this work.
Contributor Information
Sara Timm, Email: sara.timm@charite.de.
Marie Lettau, Email: marie.lettau@charite.de.
Matthias Ochs, Email: matthias.ochs@charite.de.
References
- Adamson IY, Bowden DH. The surface complexes of the lung: a cytochemical partition of phospholipid surfactant and mucopolysaccharide. Am J Pathol. 1970;61(3):359–376. [PMC free article] [PubMed] [Google Scholar]
- Aquino RS, Hayashida K, Hayashida A, Park PW. Role of HSPGs in systemic bacterial infections. Methods Mol Biol. 2022;2303:605–625. doi: 10.1007/978-1-0716-1398-6_46. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bartlett AH, Park PW. Proteoglycans in host-pathogen interactions: molecular mechanisms and therapeutic implications. Expert Rev Mol Med. 2010;12:e5. doi: 10.1017/S1462399409001367. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bennett HS. Morphological aspects of extracellular polysaccharides. J Histochem Cytochem. 1963;11(1):14–23. doi: 10.1177/11.1.14. [DOI] [Google Scholar]
- Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J, Zako M. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem. 1999;68:729–777. doi: 10.1146/annurev.biochem.68.1.729. [DOI] [PubMed] [Google Scholar]
- Boyce A, Walsh G. Production, characteristics and applications of microbial heparinases. Biochimie. 2022;198:109–140. doi: 10.1016/j.biochi.2022.03.011. [DOI] [PubMed] [Google Scholar]
- Bray BA. The role of hyaluronan in the pulmonary alveolus. J Theor Biol. 2001;210(1):121–130. doi: 10.1006/jtbi.2001.2305. [DOI] [PubMed] [Google Scholar]
- Briles DE, Paton JC, Mukerji R, Swiatlo E, Crain MJ. Pneumococcal vaccines. Microbiol Spectr. 2019 doi: 10.1128/microbiolspec.GPP3-0028-2018. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Chandra N, Liu Y, Liu JX, Frangsmyr L, Wu N, Silva LM, Lindstrom M, Chai W, Pedrosa Domellof F, Feizi T, Arnberg N. Sulfated glycosaminoglycans as viral decoy receptors for human adenovirus type 37. Viruses. 2019;11(3):247. doi: 10.3390/v11030247. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Chignalia AZ, Yetimakman F, Christiaans SC, Unal S, Bayrakci B, Wagener BM, Russell RT, Kerby JD, Pittet JF, Dull RO. The glycocalyx and trauma: a review. Shock. 2016;45(4):338–348. doi: 10.1097/SHK.0000000000000513. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Cockeran R, Anderson R, Feldman C. The role of pneumolysin in the pathogenesis of Streptococcus pneumoniae infection. Curr Opin Infect Dis. 2002;15(3):235–239. doi: 10.1097/00001432-200206000-00004. [DOI] [PubMed] [Google Scholar]
- Collins LE, Troeberg L. Heparan sulfate as a regulator of inflammation and immunity. J Leukoc Biol. 2019;105(1):81–92. doi: 10.1002/JLB.3RU0618-246R. [DOI] [PubMed] [Google Scholar]
- Dickson WH. Thorotrast : a new contrast medium for radiological diagnosis. Can Med Assoc J. 1932;27(2):125–129. [PMC free article] [PubMed] [Google Scholar]
- Donohoe BS, Mogelsvang S, Staehelin LA. Electron tomography of ER, golgi and related membrane systems. Methods. 2006;39(2):154–162. doi: 10.1016/j.ymeth.2006.05.013. [DOI] [PubMed] [Google Scholar]
- Foote CA, Soares RN, Ramirez-Perez FI, Ghiarone T, Aroor A, Manrique-Acevedo C, Padilla J, Martinez-Lemus L. Endothel Glycocalyx. Compr Physiol. 2022;12(4):3781–3811. doi: 10.1002/cphy.c210029. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gesslbauer B, Theuer M, Schweiger D, Adage T, Kungl AJ. New targets for glycosaminoglycans and glycosaminoglycans as novel targets. Expert Rev Proteom. 2013;10(1):77–95. doi: 10.1586/epr.12.75. [DOI] [PubMed] [Google Scholar]
- Groot CG. Positive colloidal thorium dioxide as an electron microscopical contrasting agent for glycosaminoglycans, compared with ruthenium red and positive colloidal iron. Histochemistry. 1981;71(4):617–627. doi: 10.1007/BF00508387. [DOI] [PubMed] [Google Scholar]
- Haeger SM, Yang Y, Schmidt EP. Heparan sulfate in the developing, healthy, and injured lung. Am J Respir Cell Mol Biol. 2016;55(1):5–11. doi: 10.1165/rcmb.2016-0043TR. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Haeger SM, Liu XY, Han XR, McNeil JB, Oshima K, McMurtry SA, Yang YM, Ouyang YL, Zhang FM, Nozik-Grayck E, Zemans RL, Tuder RM, Bastarache JA, Linhardt RJ, Schmidt EP. Epithelial heparan sulfate contributes to alveolar barrier function and is shed during lung injury. Am J Resp Cell Mol. 2018;59(3):363–374. doi: 10.1165/rcmb.2017-0428OC. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hayashida K, Aquino RS, Park PW. Coreceptor functions of cell surface heparan sulfate proteoglycans. Am J Physiol Cell Physiol. 2022;322(5):C896–C912. doi: 10.1152/ajpcell.00050.2022. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hegermann J, Lünsdorf H, Ochs M, Haller H. Visualization of the glomerular endothelial glycocalyx by electron microscopy using cationic colloidal thorium dioxide. Histochem Cell Biol. 2016;145(1):41–51. doi: 10.1007/s00418-015-1378-3. [DOI] [PubMed] [Google Scholar]
- Irvin CG, Bates JH. Measuring the lung function in the mouse: the challenge of size. Respir Res. 2003;4(1):4. doi: 10.1186/rr199. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jensen EB, Gundersen HJ, Osterby R. Determination of membrane thickness distribution from orthogonal intercepts. J Microsc. 1979;115(1):19–33. doi: 10.1111/j.1365-2818.1979.tb00149.x. [DOI] [PubMed] [Google Scholar]
- Koster AJ, Grimm R, Typke D, Hegerl R, Stoschek A, Walz J, Baumeister W. Perspectives of molecular and cellular electron tomography. J Struct Biol. 1997;120(3):276–308. doi: 10.1006/jsbi.1997.3933. [DOI] [PubMed] [Google Scholar]
- Kuhn CIII. Cytochemistry of pulmonary alveolar epithelial cells. Am J Pathol. 1968;53(5):809–833. [PMC free article] [PubMed] [Google Scholar]
- LaRiviere WB, Liao S, McMurtry SA, Oshima K, Han X, Zhang F, Yan S, Haeger SM, Ransom M, Bastarache JA, Linhardt RJ, Schmidt EP, Yang Y. Alveolar heparan sulfate shedding impedes recovery from bleomycin-induced lung injury. Am J Physiol Lung Cell Mol Physiol. 2020;318(6):L1198–L1210. doi: 10.1152/ajplung.00063.2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Laue M, Kauter A, Hoffmann T, Moller L, Michel J, Nitsche A. Morphometry of SARS-CoV and SARS-CoV-2 particles in ultrathin plastic sections of infected Vero cell cultures. Sci Rep. 2021;11(1):3515. doi: 10.1038/s41598-021-82852-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lettau M, Timm S, Dittmayer C, Lopez-Rodriguez E, Ochs M. The ultrastructural heterogeneity of lung surfactant revealed by serial section electron tomography: insights into the 3D architecture of human tubular myelin. Am J Physiol Lung Cell Mol Physiol. 2022;322(6):L873–L881. doi: 10.1152/ajplung.00020.2022. [DOI] [PubMed] [Google Scholar]
- Li H, Hao Y, Yang LL, Wang XY, Li XY, Bhandari S, Han J, Liu YJ, Gong YQ, Scott A, Smith FG, Jin SW. MCTR1 alleviates lipopolysaccharide-induced acute lung injury by protecting lung endothelial glycocalyx. J Cell Physiol. 2020;235(10):7283–7294. doi: 10.1002/jcp.29628. [DOI] [PubMed] [Google Scholar]
- Lopez-Rodriguez E, Cruz A, Richter RP, Taeusch HW, Perez-Gil J. Transient exposure of pulmonary surfactant to hyaluronan promotes structural and compositional transformations into a highly active state. J Biol Chem. 2013;288(41):29872–29881. doi: 10.1074/jbc.M113.493957. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lu KW, Goerke J, Clements JA, Taeusch HW. Hyaluronan decreases surfactant inactivation in vitro. Pediatr Res. 2005;57(2):237–241. doi: 10.1203/01.PDR.0000150726.75308.22. [DOI] [PubMed] [Google Scholar]
- Lu KW, Goerke J, Clements JA, Taeusch HW. Hyaluronan reduces surfactant inhibition and improves rat lung function after meconium injury. Pediatr Res. 2005;58(2):206–210. doi: 10.1203/01.PDR.0000169981.06266.3E. [DOI] [PubMed] [Google Scholar]
- Lünsdorf H, Kristen I, Barth E. Cationic hydrous thorium dioxide colloids: a useful tool for staining negatively charged surface matrices of bacteria for use in energy-filtered transmission electron microscopy. BMC Microbiol. 2006;6:59. doi: 10.1186/1471-2180-6-59. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Luther PK (2006) Electron tomography methods for three-dimensional visualization of structures in the cell. Sample shrinkage and radiation damage of plastic sections. Springer, New York
- Martins MD, Bairos VA. Glycocalyx of lung epithelial cells. Int Rev Cytol Surv Cell Biol. 2002;216(216):131–173. doi: 10.1016/s0074-7696(02)16005-0. [DOI] [PubMed] [Google Scholar]
- Masola V, Zaza G, Arduini A, Onisto M, Gambaro G. Endothelial glycocalyx as a regulator of fibrotic processes. Int J Mol Sci. 2021;22(6):2996. doi: 10.3390/ijms22062996. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Mitchell TJ, Walker JA, Saunders FK, Andrew PW, Boulnois GJ. Expression of the pneumolysin gene in Escherichia coli: rapid purification and biological properties. Biochim Biophys Acta. 1989;1007(1):67–72. doi: 10.1016/0167-4781(89)90131-0. [DOI] [PubMed] [Google Scholar]
- Mockl L. The emerging role of the mammalian glycocalyx in functional membrane organization and immune system regulation. Front Cell Dev Biol. 2020;8:253. doi: 10.3389/fcell.2020.00253. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Morla S. Glycosaminoglycans and glycosaminoglycan mimetics in cancer and inflammation. Int J Mol Sci. 2019;20(8):1963. doi: 10.3390/ijms20081963. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Morris A, Wang B, Waern I, Venkatasamy R, Page C, Schmidt EP, Wernersson S, Li JP, Spina D. The role of heparanase in pulmonary cell recruitment in response to an allergic but not non-allergic stimulus. PLoS One. 2015;10(6):e0127032. doi: 10.1371/journal.pone.0127032. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Nollmann M, Gilbert R, Mitchell T, Sferrazza M, Byron O. The role of cholesterol in the activity of pneumolysin, a bacterial protein toxin. Biophys J. 2004;86(5):3141–3151. doi: 10.1016/S0006-3495(04)74362-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ochs M, Hegermann J, Lopez-Rodriguez E, Timm S, Nouailles G, Matuszak J, Simmons S, Witzenrath M, Kuebler WM. On top of the alveolar epithelium: surfactant and the glycocalyx. Int J Mol Sci. 2020;21(9):3075. doi: 10.3390/ijms21093075. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Paavolainen L, Acar E, Tuna U, Peltonen S, Moriya T, Soonsawad P, Marjomaki V, Cheng RH, Ruotsalainen U. Compensation of missing wedge effects with sequential statistical reconstruction in electron tomography. PLoS One. 2014;9(10):e108978. doi: 10.1371/journal.pone.0108978. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Patterson EK, Cepinskas G, Fraser DD. Endothelial glycocalyx degradation in critical illness and injury. Front Med (Lausanne) 2022;9:898592. doi: 10.3389/fmed.2022.898592. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pereira JM, Xu S, Leong JM, Sousa S. The yin and yang of pneumolysin during pneumococcal infection. Front Immunol. 2022;13:878244. doi: 10.3389/fimmu.2022.878244. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Puchwein-Schwepcke A, Genzel-Boroviczeny O, Nussbaum C. The endothelial glycocalyx: physiology and pathology in neonates, infants and children. Front Cell Dev Biol. 2021;9:733557. doi: 10.3389/fcell.2021.733557. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rajas O, Quiros LM, Ortega M, Vazquez-Espinosa E, Merayo-Lloves J, Vazquez F, Garcia B. Glycosaminoglycans are involved in bacterial adherence to lung cells. BMC Infect Dis. 2017;17(1):319. doi: 10.1186/s12879-017-2418-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rayner CFJ, Jackson AD, Rutman A, Dewar A, Mitchell TJ, Andrew PW, Cole PJ, Wilson R. Interaction of pneumolysin-sufficient and -deficient isogenic variants of Streptococcus pneumoniae with human respiratory mucosa. Infect Immun. 1995;63(2):442–447. doi: 10.1128/Iai.63.2.442-447.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Reynolds ES. The use of lead citrate at high pH as an electron-opaque stain in electron microscopy. J Cell Biol. 1963;17:208–212. doi: 10.1083/jcb.17.1.208. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rizzo AN, Schmidt EP. The role of the alveolar epithelial glycocalyx in acute respiratory distress syndrome. Am J Physiol Cell Physiol. 2023;324(4):C799–C806. doi: 10.1152/ajpcell.00555.2022. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rizzo AN, Haeger SM, Oshima K, Yang Y, Wallbank AM, Jin Y, Lettau M, McCaig LA, Wickersham NE, McNeil JB, Zakharevich I, McMurtry SA, Langouet-Astrie CJ, Kopf KW, Voelker DR, Hansen KC, Shaver CM, Kerchberger VE, Peterson RA, Kuebler WM, Ochs M, Veldhuizen RA, Smith BJ, Ware LB, Bastarache JA, Schmidt EP. Alveolar epithelial glycocalyx degradation mediates surfactant dysfunction and contributes to acute respiratory distress syndrome. JCI Insight. 2022;7(2):e154573. doi: 10.1172/jci.insight.154573. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Roth J. Ultrahistochemical demonstration of saccharide components of complex carbohydrates at alveolar cell-surface and at mesothelial cell-surface of pleura visceralis of mice by means of concanavalin A. Exp Pathol-Jena. 1973;8(3):157–167. [PubMed] [Google Scholar]
- Rubins JB, Charboneau D, Paton JC, Mitchell TJ, Andrew PW, Janoff EN. Dual function of pneumolysin in the early pathogenesis of murine pneumococcal pneumonia. J Clin Invest. 1995;95(1):142–150. doi: 10.1172/JCI117631. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sanderson RD, Elkin M, Rapraeger AC, Ilan N, Vlodavsky I. Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy. FEBS J. 2017;284(1):42–55. doi: 10.1111/febs.13932. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sauer A, Seeliger B, Jandl K, Erfinanda L, Wilhelm J, Alexopoulos I, Baal N, Birnhuber A, David S, Welte T, Barreto G, Gaertner U, Kwapiszewska G, Seeger W, Kuebler WM, Schaefer L, Wygrecka M, members of the CSG Circulating hyaluronic acid signature in CAP and ARDS - the role of pneumolysin in hyaluronic acid shedding. Matrix Biol. 2022;114:67–83. doi: 10.1016/j.matbio.2022.11.003. [DOI] [PubMed] [Google Scholar]
- Schmidt EP, Yang Y, Janssen WJ, Gandjeva A, Perez MJ, Barthel L, Zemans RL, Bowman JC, Koyanagi DE, Yunt ZX, Smith LP, Cheng SS, Overdier KH, Thompson KR, Geraci MW, Douglas IS, Pearse DB, Tuder RM. The pulmonary endothelial glycocalyx regulates neutrophil adhesion and lung injury during experimental sepsis. Nat Med. 2012;18(8):1217–1223. doi: 10.1038/nm.2843. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Seffer MT, Cottam D, Forni LG, Kielstein JT. Heparin 2.0: a new approach to the infection crisis. Blood Purif. 2021;50(1):28–34. doi: 10.1159/000508647. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Souza-Fernandes AB, Pelosi P, Rocco PR. Bench-to-bedside review: the role of glycosaminoglycans in respiratory disease. Crit Care. 2006;10(6):237. doi: 10.1186/cc5069. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Stover BJ. Effects of thorotrast in humans. Health Phys. 1983;44(Suppl 1):253–257. doi: 10.1097/00004032-198306001-00022. [DOI] [PubMed] [Google Scholar]
- Suzuki A, Tomita H, Okada H. Form follows function: the endothelial glycocalyx. Transl Res. 2022;247:158–167. doi: 10.1016/j.trsl.2022.03.014. [DOI] [PubMed] [Google Scholar]
- Tschanz S, Schneider JP, Knudsen L. Design-based stereology: planning, volumetry and sampling are crucial steps for a successful study. Ann Anat. 2014;196(1):3–11. doi: 10.1016/j.aanat.2013.04.011. [DOI] [PubMed] [Google Scholar]
- Uchimido R, Schmidt EP, Shapiro NI. The glycocalyx: a novel diagnostic and therapeutic target in sepsis. Crit Care. 2019;23(1):16. doi: 10.1186/s13054-018-2292-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Vignero J, Marshall NW, Vande Velde G, Bliznakova K, Bosmans H. Translation from murine to human lung imaging using x-ray dark field radiography: a simulation study. PLoS One. 2018;13(10):e0206302. doi: 10.1371/journal.pone.0206302. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wang Q, Chi L. The alterations and roles of glycosaminoglycans in human diseases. Polymers (Basel) 2022;14(22):5014. doi: 10.3390/polym14225014. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Weidenfeld S, Kuebler WM. Shedding first light on the alveolar epithelial glycocalyx. Am J Respir Cell Mol Biol. 2018;59(3):283–284. doi: 10.1165/rcmb.2018-0108ED. [DOI] [PubMed] [Google Scholar]
- Wigen J, Elowsson-Rendin L, Karlsson L, Tykesson E, Westergren-Thorsson G. Glycosaminoglycans: a link between development and regeneration in the lung. Stem Cells Dev. 2019;28(13):823–832. doi: 10.1089/scd.2019.0009. [DOI] [PubMed] [Google Scholar]
- Witzenrath M, Ahrens B, Kube SM, Braun A, Hoymann HG, Hocke AC, Rosseau S, Suttorp N, Hamelmann E, Schutte H. Detection of allergen-induced airway hyperresponsiveness in isolated mouse lungs. Am J Physiol Lung Cell Mol Physiol. 2006;291(3):L466–472. doi: 10.1152/ajplung.00011.2005. [DOI] [PubMed] [Google Scholar]
- Witzenrath M, Gutbier B, Hocke AC, Schmeck B, Hippenstiel S, Berger K, Mitchell TJ, et al. Role of pneumolysin for the development of acute lung injury in pneumococcal pneumonia. Crit Care Med. 2006;34(7):1947–1954. doi: 10.1097/01.CCM.0000220496.48295.A9. [DOI] [PubMed] [Google Scholar]
- Woodhead M. Community-acquired pneumonia in Europe: causative pathogens and resistance patterns. Eur Respir J Suppl. 2002;36:20s–27s. doi: 10.1183/09031936.02.00702002. [DOI] [PubMed] [Google Scholar]
- Wu L, Davies GJ. An overview of the structure, mechanism and specificity of human heparanase. Adv Exp Med Biol. 2020;1221:139–167. doi: 10.1007/978-3-030-34521-1_5. [DOI] [PubMed] [Google Scholar]
- Zhang D, Zhang JT, Pan Y, Liu XF, Xu JW, Cui WJ, Qiao XR, Dong L. Syndecan-1 shedding by matrix metalloproteinase-9 signaling regulates alveolar epithelial tight junction in lipopolysaccharide-induced early acute lung injury. J Inflamm Res. 2021;14:5801–5816. doi: 10.2147/JIR.S331020. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
The datasets generated and analyzed during the current study are available from the corresponding authors on reasonable request.